PINK1-Parkin Pathway Activity Is Regulated by Degradation of PINK1 in the Mitochondrial Matrix

Ruth E. Thomas¹, Laurie A. Andrews¹, Jonathon L. Burman¹, Wen-Yang Lin², Leo J. Pallanck¹*

¹ Department of Genome Sciences, University of Washington, Seattle, Washington, United States of America, ² Department of Biology, University of Washington, Seattle, Washington, United States of America

Abstract
Loss-of-function mutations in PINK1, which encodes a mitochondrially targeted serine/threonine kinase, result in an early-onset heritable form of Parkinson's disease. Previous work has shown that PINK1 is constitutively degraded in healthy cells, but selectively accumulates on the surface of depolarized mitochondria, thereby initiating their autophagic degradation. Although PINK1 is known to be a cleavage target of several mitochondrial proteases, whether these proteases account for the constitutive degradation of PINK1 in healthy mitochondria remains unclear. To explore the mechanism by which PINK1 is degraded, we performed a screen for mitochondrial proteases that influence PINK1 abundance in the fruit fly Drosophila melanogaster. We found that genetic perturbations targeting the matrix-localized protease Lon caused dramatic accumulation of processed PINK1 species in several mitochondrial compartments, including the matrix. Knockdown of Lon did not decrease mitochondrial membrane potential or trigger activation of the mitochondrial unfolded protein stress response (UPRmt), indicating that PINK1 accumulation in Lon-deficient animals is not a secondary consequence of mitochondrial depolarization or the UPRmt. Moreover, the influence of Lon on PINK1 abundance was highly specific, as Lon inactivation had little or no effect on the abundance of other mitochondrial proteins. Further studies indicated that the processed forms of PINK1 that accumulate upon Lon inactivation are capable of activating the PINK1-Parkin pathway in vivo. Our findings thus suggest that Lon plays an essential role in regulating the PINK1-Parkin pathway by promoting the degradation of PINK1 in the matrix of healthy mitochondria.

Introduction

The accumulation of defective mitochondria is strongly implicated in aging, as well as a variety of common age-related diseases [1,2,3]. To counteract this accumulation, cells have evolved a number of mitochondrial quality control pathways. While previous work has revealed molecular mechanisms involved in the prevention and repair of mitochondrial damage [4,5,6], the mechanism by which defective mitochondria are selectively detected and degraded was unknown until relatively recently. Over the past several years, studies of the PINK1/Parkin pathway have dramatically advanced our understanding of the mechanisms underlying mitochondrial quality control, many questions remain unanswered. One of the most important of these questions concerns the mechanism of PINK1 degradation by healthy mitochondria. Constitutive elimination of PINK1 prevents healthy mitochondria from being inappropriately destroyed, but permits a rapid response when PINK1 degradation ceases due to mitochondrial dysfunction. Previous work has identified three mitochondrially localized proteases that appear to participate in PINK1 proteolytic processing: mitochondrial processing peptidase (MPP) [12]; AFG3-like AAA ATPase 2 (AFG3L2) [12]; and Rhomboid-7/Presenilin-associated rhomboid-like protein, mitochondrial (Rho-7/PARL) [13,14]. MPP removes the N-terminal mitochondrial targeting sequence of PINK1 and many other mitochondrial proteins [15]. The processing event mediated by AFG3L2 is unknown, although previous work suggests that AFG3L2 may facilitate the Rho-7/PARL cleavage event [12]. Rho-7/PARL cleaves PINK1 within its transmembrane domain [14,16], creating a form of PINK1 that is released to the cytosol and degraded by the proteasome [17,18,19]. However, not all PINK1 degradation is dependent on Rho-7/PARL [12,13,14], suggesting that there are other mechanisms of PINK1 degradation.
Lon Regulates PINK1 Degradation and Activity

Author Summary
Mitochondria are essential organelles that provide most of the cell’s energy and perform many other critical functions. The gradual accumulation of defective mitochondria is thought to play a role in aging and in diseases of the nervous system, including Parkinson’s disease. The selective elimination of defective mitochondria is therefore a vital task for the cell, and the protein PINK1 was recently identified as a critical player in this process. PINK1 accumulates on the surface of mitochondria after they are damaged, starting a process that leads ultimately to the elimination of defective mitochondria. Previous work indicated that PINK1 does not accumulate on healthy mitochondria because it is rapidly degraded. However, it was unclear exactly how and where this degradation occurred. Our work shows that Lon protease promotes the degradation of PINK1 in the mitochondrial matrix. This finding provides new insight into the mechanisms of mitochondrial quality control, and reveals a potential strategy for treating the many diseases associated with the accumulation of defective mitochondria.

To explore the mechanisms by which PINK1 is degraded, we used the fruit fly Drosophila melanogaster to conduct a screen for mitochondrial proteases that affect PINK1 processing and stability in vivo. Our work indicates that PINK1 is directed to the mitochondrial matrix, where it is degraded by the matrix-localized Lon protease. We also found that inactivation of Lon leads to the accumulation of cleaved forms of PINK1 that are active in vivo. Thus, Lon appears to represent a critical component of the mitochondrial proteolytic machinery that opposes PINK1 accumulation on the surface of healthy mitochondria.

Results
Lon protease influences PINK1 abundance
To identify proteases that influence PINK1 stability, we used the pan-neuronal driver elav-GAL4 to express RNA interference (RNAi) constructs targeting known mitochondrial proteases in a fly strain that also bears a transgene with a mCherry-tagged form of PINK1 (Table S1). To avoid overexpression artifacts associated with the UAS/GAL4 system, we used a transgenic line that expresses PINK1-Myc under the control of the endogenous PINK1 promoter [20]. Flies bearing this transgene have only a small increase in PINK1 expression and exhibit no detectable abnormalities (Fig. S1 and data not shown). We then performed anti-Myc immunoblotting on head protein extracts from flies co-expressing the PINK1 transgene and the GAL4-driven RNAi constructs to assess the effects of protease knockdown on PINK1 processing and abundance. The anti-Myc antiseraum detected four bands in protein extracts from flies expressing a control RNAi targeting an exogenous gene (mCherry, hereafter Control-R) (Fig. S2A). We propose that the highest molecular weight (MW) PINK1 band corresponds to unprocessed, full-length PINK1 (FL-PINK1). The second highest MW PINK1 band differs from the highest MW band by a mass consistent with that of the predicted PINK1 mitochondrial targeting sequence, so we propose that this band is the MPP-processed form of PINK1 (MPP-PINK1). The third highest MW PINK1 band corresponds in size to the Rho-7/PARL-processed form of PINK1 (Rho-PINK1), as identified previously [13]. The origin of the lowest MW PINK1 band is uncertain, but appears to be dependent on the AFG3L2 protease, as this band was nearly absent in AFG3L2-deficient animals (Fig. S2A, B). This finding led us to name the lowest PINK1 band AFG-PINK1. Among the 13 mitochondrial proteases tested in our study, only RNAi constructs targeting AFG3L2 (CG6512) and Lon protease (CG8798) resulted in accumulation of PINK1 (Table S1). For the remainder of our studies we focused on Lon as Lon involvement in PINK1 processing had not been previously characterized.

RNAi-mediated knockdown of Lon led to a dramatic accumulation of all three processed PINK1 isoforms (Fig. 1A, B). Importantly, the effects of Lon knockdown were reproduced with two independent Lon RNAi constructs, and the magnitude of PINK1 accumulation correlated with the extent of Lon knockdown (Fig. 1B–D), indicating that PINK1 accumulation is a consequence of Lon inactivation, rather than an RNAi off-target effect. Thus, our finding that MPP-PINK1, Rho-PINK1, and AFG-PINK1 accumulate upon Lon inactivation raises the possibility that these PINK1 isoforms are substrates of Lon-mediated matrix degradation. However, before testing this model further, we explored other possible explanations of our findings.

Lon has been shown to degrade a number of mitochondrial proteins [21,22], and is also implicated in mitochondrial DNA (mtDNA) stability [23,24,25] and in the mitochondrial unfolded protein stress response [26]. Recently published work also suggests that mitochondrial unfolded protein stress triggers activation of the PINK1-Parkin pathway [27]. Thus, PINK1 accumulation in response to Lon knockdown could be a downstream consequence of a generalized matrix protein degradation defect, mtDNA instability, or the mitochondrial unfolded protein response (UPRmt). However, knockdown of Lon did not influence the abundance of the inner membrane–associated matrix proteins Complex V β (Comp V β) or NADH dehydrogenase (ubiquinone) Fe-S protein 3 (NDUFS3) (Fig. 2A), and only mildly affected the abundance of a known Lon substrate, Mitochondrial transcription factor A (TFAM). Moreover, the effect of Lon knockdown on TFAM abundance was only seen in flies expressing the stronger Lon RNAi construct, Lon-R2 (Fig. 1E). Knockdown of Lon also had no effect on mtDNA abundance (Fig. S3), or on the abundance of Heat shock protein 60 (Hsp60), a marker of the UPRmt (Fig. 1C, F). Thus, PINK1 accumulation appears to be a relatively specific consequence of Lon inactivation rather than a downstream consequence of a general matrix protein degradation defect, mtDNA instability, or UPRmt activation.

Because PINK1 accumulates in cell culture upon mitochondrial depolarization [10,11], another potential explanation of our findings is that Lon inactivation triggers mitochondrial depolarization. To explore this possibility, we used a recently described procedure to measure mitochondrial membrane potential in the adult Drosophila nervous system [28]. Briefly, we dissociated the brains from flies expressing either a control RNAi or RNAi targeting Lon to create neural cell suspensions. We then stained the cell suspensions with the mitochondrial membrane potential–dependent dye tetramethylrhodamine, ethyl ester (TMRE), and used flow cytometry to compare the distribution of mitochondrial membrane potential in these cell populations. Neither of the RNAi constructs targeting Lon caused a significant reduction of mitochondrial membrane potential (Fig. 1G). Rather, there was a trend for the stronger Lon RNAi construct, Lon-R2, to cause hyperpolarization. These findings indicate that the increased PINK1 abundance upon Lon inactivation is not due to decreased mitochondrial membrane potential. We therefore performed additional studies to explore the role of Lon in PINK1 processing.
Figure 1. PINK1 accumulates upon knockdown of Lon. (A) Western blot analysis of whole head homogenates from transgenic flies expressing a Myc-tagged PINK1 genomic construct and a UAS-RNAi construct driven by elav-GAL4. The RNAi constructs used were as follows: the non-specific control mCherry-RNAi (Control-R), Lon-RNAi1 (Lon-R1), and Lon-RNAi2 (Lon-R2). An anti-Myc antibody was used to detect PINK1 and an anti-Actin antibody was used as a protein loading control. (B) Densitometry of the PINK1-Myc bands from the indicated genotypes was performed using Fiji software. The PINK1-Myc band intensities were then normalized to their respective Actin loading controls, and these ratios were in turn normalized to
Lon promotes PINK1 degradation in the mitochondrial matrix

Because Lon is a matrix-localized protease, the simplest interpretation of our findings is that Lon promotes the degradation of PINK1 in the mitochondrial matrix. This model predicts that Lon inactivation should result in the accumulation of PINK1 in the matrix. To test this model, we first examined the subcellular localization of the accumulated PINK1 isoforms following knockdown of Lon, using differential sedimentation to generate mitochondrial and postmitochondrial supernatant fractions. Previous work has shown that Rho-PINK1 can be released into the cytosol, where it is degraded by the proteasome [17,18,19]. Consistent with this work, we found that most of the PINK1 protein in control animals consisted of Rho-PINK1 in the supernatant fraction (Fig. 2A). We also detected lesser amounts of Rho-PINK1 in the mitochondrial fraction, and faint bands of MPP-PINK1 in the mitochondrial and the postmitochondrial supernatant fractions of control animals, suggesting that MPP-PINK1 can also be released from mitochondria (Fig. 2A). RNAi-mediated inactivation of Lon resulted in the accumulation of all processed forms of PINK1, including AFG-PINK1, in both the mitochondrial and postmitochondrial supernatant fractions, particularly in the case of the stronger Lon-R2 construct (Fig. 2). However, by far the largest increases in PINK1 accumulation upon Lon inactivation were seen in the mitochondrial fraction (compare 2B-D with 2E-G), consistent with the model that Lon promotes PINK1 degradation in the mitochondrial matrix. The finding that Lon inactivation also results in the accumulation of PINK1 in the postmitochondrial supernatant fraction raises the possibility that Lon is also required for the efficient import of PINK1 into the matrix.

To test whether the PINK1 that accumulates in mitochondrial fractions from Lon-deficient animals resides in the matrix, we performed protease protection experiments on isolated mitochondria. Specifically, we compared the Proteinase K (ProK) digestion sensitivities of the various PINK1 isoforms to the sensitivities of Mitofilusin (Mfn), Complex V β (Comp V β), and pyruvate dehydrogenase (PDH), which reside on the outer mitochondrial membrane, on the matrix side of the inner membrane, and in the matrix lumen, respectively. Treating a mitochondrial fraction from control flies with a low concentration of ProK (0.5 µg/ml) resulted in substantial degradation of Mfn but did not significantly influence the abundance of Comp V β, PDH, or PINK1 (Fig. 3A–D). However, disrupting mitochondrial membranes with Triton X-100 followed by ProK treatment at a low concentration (0.5 µg/ml) resulted in nearly complete degradation of Comp V β, PDH, and PINK1 in both control and Lon-deficient animals (Fig. S4), indicating that the resistance of these proteins to ProK degradation in intact mitochondria (Fig. 3A–D) is a consequence of their internal localization rather than of inherent ProK insensitivity. Upon treatment of mitochondria from Lon-deficient animals with a low concentration (0.5 µg/ml) of ProK, the MPP-PINK1 and AFG3-PINK1 isoforms were 40% depleted (Fig. 3F). This finding is consistent with the model that Lon protease promotes the import and degradation of PINK1 in the mitochondrial matrix.

Lon regulates PINK1-Parkin pathway activity in vivo

Previous work has shown that the accumulation of PINK1 on the mitochondrial outer membrane triggers the recruitment of Parkin and the eventual degradation of mitochondria [10,11]. Thus, our finding that some of the excess MPP-processed and mitochondrial fractions from Lon-deficient animals were substantially depleted only at ProK concentrations that also resulted in depletion of Comp V β and PDH (5 and 10 µg/ml; Fig. 3F). These findings indicate that PINK1 accumulates in both the outer membrane and the matrix upon Lon inactivation, consistent with the model that Lon protease promotes the import and degradation of PINK1 in the mitochondrial matrix.
AFG3L2-processed PINK1 in Lon-deficient animals accumulates on the mitochondrial outer membrane raises the possibility that Lon inactivation might trigger PINK1-Parkin pathway activity. In potential support of this hypothesis, there is a trend towards increased mitochondrial membrane potential in Lon-deficient animals that mirrors the increased mitochondrial membrane potential seen in flies overexpressing PINK1 [28]. We performed several experiments to test this hypothesis directly.

To determine whether inactivation of Lon influences PINK1-Parkin pathway activity in vivo, we first explored the influence of...
Figure 3. PINK1 accumulates on the outer membrane and in the matrix upon knockdown of Lon. (A) Mitochondrial fractions isolated from the heads of flies expressing Control-R were divided in half. One of the two samples was treated with 0.5 µg/ml Proteinase K and both samples were incubated at 4°C for 20 minutes. Samples were then subjected to western blot analysis using antibodies to the outer membrane protein Mitofusin (Mfn), the inner membrane–associated matrix protein Complex V β (Comp V β), and the matrix luminal protein pyruvate dehydrogenase (PDH). elav-GAL4 was used to drive expression of all the RNAi constructs used in this and the following experiments. (B) Densitometry of Mfn, Comp V β, and PDH bands from experiments represented by panel A were performed using Fiji software, and the ratios of the band intensities in the sample containing ProK to the sample lacking ProK are shown. (C) Mitochondrial fractions isolated from the heads of flies expressing Control-R and PINK1-Myc were divided in half. Each sample was treated with the indicated concentrations of ProK. Following incubation, samples were subjected to...
Lon deficiency on a PINK1 overexpression phenotype. We have previously shown that overexpressing PINK1 in a variety of Drosophila tissues is toxic, and that this toxicity can be suppressed by homozygous loss-of-function mutations in parkin and dramatically enhanced by co-overexpression of Parkin [32]. These and other findings indicate that the toxicity associated with PINK1 overexpression results from an amplification of PINK1-Parkin pathway activity. A convenient way to quantify this toxicity involves monitoring the extent to which the structure of the compound eye becomes disorganized when PINK1 is overexpressed in the eye using the ey-GAL4 driver. We used this approach to test the influence of Lon on PINK1-Parkin pathway activity. Both RNAi constructs targeting Lon significantly enhanced (worsened) the PINK1 overexpression phenotype (Fig. 5A), as would be predicted if Lon normally acts to restrict PINK1 activity. Moreover, the enhancement produced by these RNAi constructs correlated with their efficiency in reducing Lon expression, and with their effectiveness in triggering PINK1 accumulation (Fig. 1A, B). Neither of the Lon RNAi constructs detectably influenced eye structure when driven with the ey-GAL4 driver in an otherwise WT background (Fig. S5), suggesting that the enhancement of the PINK1 overexpression phenotype conferred by these RNAi constructs is not simply an additive effect of combining two unrelated perturbations that affect the eye.

Next we examined the effects of a P-element insertion and a deletion targeting Lon on a thoracic indentation phenotype produced by PINK1 deficiency in the flight muscle. Previous work has shown that thoracic indentations serve as a reliable surrogate marker of muscle pathology in PINK1- and parkin mutants [20,32,33,34]. We used an RNAi line targeting PINK1 that yields a hypomorphic phenotype, because decreases in Lon activity would not be expected to improve a PINK1 null phenotype. We also avoided the use of RNAi constructs targeting Lon because the introduction of any additional UAS element suppressed the thoracic indentation phenotype caused by PINK1 RNAi, likely through a GAL4 dilution effect (data not shown). We found that a heterozygous P-element insertion mutation in Lon suppressed the PINK1-RNAi thoracic indentation phenotype (Fig. 5B) but did not influence the thoracic indentation frequency of PINK1 null mutants, confirming that Lon deficiency suppresses the phenotype only when some PINK1 is present (Fig. S6). Additionally, a heterozygous deletion that completely removes Lon caused even stronger suppression (Fig. 5B). Together, our findings indicate that the PINK1 isoforms that accumulate upon knockdown of Lon are capable of triggering PINK1-Parkin pathway activity in vivo, and demonstrate that Lon plays an important role in regulating the PINK1-Parkin pathway.

Discussion

Previous work has shown that PINK1 protein is normally maintained at low levels in healthy cells [10,11]. While the proteasome appears to be responsible for the degradation of a cytosolic Rho-7/PARL-processed form of PINK1 [17,18], and thus at least partially accounts for the low abundance of PINK1 in healthy cells (Fig. 6A–C), whether PINK1 degradation also occurred in mitochondria remained unclear from previous work. Our study identifies Lon as a protease involved in PINK1 processing and degradation in the mitochondrial matrix (Fig. 6D). Lon may also serve to assist the import of PINK1 into the matrix, given that MPP-PINK1 and AFG-PINK1 accumulate on the mitochondrial surface and in the cytosol upon Lon inactivation. Lon could facilitate PINK1 import into the matrix through its known unfoldase activity, ultimately delivering PINK1 to the Lon protease domain for degradation [35]. While a recent study in vertebrate cell culture also identified the mitochondrial matrix protein AFG3L2 as a PINK1 processing protease, the exact role of AFG3L2 in PINK1 processing was not established [12]. Our work suggests that AFG3L2 is responsible for producing a cleaved form of PINK1, AFG-PINK1. Moreover, our finding that AFG-PINK1 accumulates to a greater extent than other PINK1 isoforms upon Lon inactivation (Fig. 2) further suggests that AFG-PINK1 is the preferred substrate for Lon. Together, our findings support a model in which AFG3L2 and Lon play important roles in mitochondrial quality control, by promoting degradation of PINK1 within the mitochondrial matrix to prevent healthy mitochondria from being targeted for mitophagy.

Our finding that Lon plays a role in the degradation of PINK1 contrasts with two recent papers that examined the effect of Lon knockdown on PINK1 levels in cultured cells [12,27]. Neither Greene et al. [12] nor Jin et al. [27] observed dramatic accumulation of PINK1 when Lon was targeted by shRNA. There are several possible explanations for this discrepancy. One potential explanation is that mammalian Lon may be highly efficient at degrading PINK1, such that even a small amount of Lon activity may be sufficient to fully degrade PINK1. Another potential explanation is that the cultured cells were able to compensate for reduced Lon activity through increased cytoplasmic release of Rho-7/PARL-processed PINK1 for proteasomal degradation. It should also be noted that while Greene et al. and Jin et al. did not observe dramatic accumulation of PINK1 upon Lon knockdown, both these groups and others have reported PINK1 accumulation upon MG132 treatment [12,14,18,36]; while MG132 is best known as a proteasome inhibitor, it is also a potent inhibitor of Lon [37]. Moreover, Jin et al. observed PINK1 accumulation upon expression of an unfolded protein targeted to the matrix (a deletion mutant of ornithine carbamoyltransferase, ΔOTC), and PINK1 accumulation was further enhanced by simultaneously knocking down Lon. From these findings Jin et al. posit that when the UPRmit is insufficient to mitigate mitochondrial stress, PINK1 import is inhibited through an unknown mechanism, thus triggering mitophagy. However, an alternative interpretation of their findings is that ΔOTC acts as a competitive inhibitor of PINK1 degradation by Lon, which is known to degrade unfolded proteins [35]. This model would account for both the accumulation of PINK1 seen upon expression of ΔOTC, and the increased accumulation of PINK1 and ΔOTC that is seen when Lon is knocked down. Further studies will be required to distinguish these models.
Lon Regulates PINK1 Degradation and Activity

A
Miro-Myc

B
Opa1-FLAG

C
Cyto C

D
PINK1-Myc

E
Lon-R1 PINK1-Myc

F

Fraction of co-localization

0.05 0.10 0.15 0.20 0.25 0.30 0.35
Miro-Myc Opa1-FLAG Cyto C PINK1-Myc Lon-R1 PINK1-Myc
is rapid and efficient, one would not expect to detect significant amounts of PINK1 in the mitochondrial matrix except when Lon function is impaired. Indeed, our biochemical experiments are in general agreement with previously published work, as we also detected little PINK1 in mitochondrial fractions from WT control animals. Although previous work indicated that the accumulation of FL-PINK1 on the outer surface of depolarized mitochondria triggers the activation of the PINK1-Parkin pathway [10,11], it was unclear whether other processed forms of PINK1 could also trigger pathway activation. Our findings demonstrating that Lon inactivation results in the accumulation of MPP-PINK1 and AFG-PINK1 on the outer mitochondrial membrane, and causes increased PINK1-Parkin pathway activity in vivo, suggest that one or both of these forms of PINK1 are also capable of activating the PINK1-Parkin pathway. Recent work also suggests that the PARL-processed form of PINK1 can promote pathway activity, as it can associate with mitochondria in vitro and promote the recruitment of Parkin [40]. However, because FL-PINK1 appears to be the only form of PINK1 that accumulates upon mitochondrial depolarization [10], processed forms of PINK1 may not normally participate in pathway activity. They may, however, have other important biological roles. In particular, recent studies implicate PINK1 in phosphorylation [41] and selective turnover [42,43] of matrix-localized proteins; our finding that processed forms of PINK1 localize at least transiently to the matrix raises the possibility that PINK1 directly mediates these processes. Future work will be needed to fully delineate these possibilities, as well as to explore the possible therapeutic benefits of Lon inhibition in treating the many diseases associated with accumulation of defective mitochondria, including Parkinson’s disease.

Materials and Methods

Fly stocks

*Drosophila* stocks were maintained on standard cornmeal-molasses food at 25°C. The PINK1-myc transgenic line, *UAS-PINK1* transgenic line, *UAS-Mito-myc* transgenic line, *Mito-GAL4* driver line and *Dme2-GAL4* driver line have been previously described [20,34,44,45,46]. The following lines were obtained from the Bloomington Drosophila Stock Center: *elav-GAL4*, *cy-GAL4*, *sqh-mito-EYFP*, *LonEP*, *Df(3L)Exel9011*, *P{VALIUM20-mCherry}attP2* (Control-RNAi), and *P{TRiP.KHS01060}attP2* (Lon-RNAi). The *P{GD11396}21860* (PINK1-RNAi), *P{KK101663}109629* (AFG3L2-RNAi), and *P{GD14050}36036* (Lon-RNAi1) RNAi lines were obtained from the Vienna Drosophila Resource Center. All other RNAi lines tested were obtained from the stock centers indicated in Table S1.

qPCR analysis

For measurement of *PINK1* mRNA, total RNA was extracted from *elav-GAL4; Control-R/+* and *elav-GAL4; Control-R*/PINK1-myc using TRIzol (#15596-026, Life Technologies). Reverse transcription was done using the iScript cDNA Synthesis kit (#170-8890, Bio-Rad) and diluted 1:50 and 1:300 before use in qPCR reactions. Primer sequences for *PINK1* and *Rap2l* were obtained from the Fly Primer Bank [47]. Primer pairs P60267 and P233832 were used for *PINK1*, and primer pair P8673 for *Rap2l*. The log method was used to calculate fold change. *Rap2l* was used as the internal control, as the expression of this gene has been reported as the most invariant across different genotypes and ages [48]. qPCR was performed using Brilliant III Ultra-Fast SYBR Green QPCR Master Mix (#600882, Agilent Technologies) and a Bio-Rad Opticon 2 machine. Mitochondrial and nuclear DNA abundance were measured by using the DNA extraction method and primers

Figure 5. Lon deficiency stimulates PINK1 activity in vivo. (A) The eye severity score of flies co-overexpressing PINK1 with Control-R (*n = 74*), Lon-R1 (*n = 163*), or Lon-R2 (*n = 90*) using the ey-GAL4 driver. (B) Comparison of the frequency of thoracic indentations in flies expressing the PINK1-RNAi construct (PINK1-R) in an otherwise wild-type background to the frequency in animals that also bear heterozygous mutations in Lon: PINK1-RNAi+/+ (*n = 306*), PINK1-RNAi LonR1+/+ (*n = 74*), and PINK1-RNAi LonR2+/+ (*n = 83*). LonR1 refers to the LonR1allele of Lon, and LonR2 refers to the Df(3L)Exel9011 deletion that removes the Lon gene along with several other genes. The Dme2-GAL4 driver was used to drive expression of the PINK1-R construct in experiments described in panel B. Error bars represent s.e.m. *p < 0.05,* **p < 0.005 by Student t test.

doi:10.1371/journal.pgen.1004279.g005

Figure 4. PINK1 accumulates in the mitochondrial matrix upon knockdown of Lon. Immunofluorescent staining of thoracic muscles expressing matrix-targeted YFP (Mito-YFP) under control of the sqh genomic promoter, together with either (A) Myc-tagged Mitochondrial Rho (Mito-Myc), (B) FLAG-tagged Optic atrophy 1 (Opal1-FLAG), (C) endogenous Cytochrome C (Cyto C), (D) Myc-tagged PINK1 (PINK1-Myc), or (E) Lon-RNAi1 (Lon-R1) and PINK1-Myc. The muscle-specific Mhc-GAL4 driver was used to drive expression of Mito-Myc in panel A and Opal1-FLAG in panel B, and the muscle-specific Dme2-GAL4 driver was used to drive expression of Lon-R1 in panel E. (F) We determined the percent volume shared between green objects (representing the matrix marker Mito-YFP) and red objects (representing the mitochondrial proteins analyzed in A–E). Red objects that shared at least 60% of their volume with Mito-YFP were considered to co-localize. Bar represents 2 μm.

doi:10.1371/journal.pgen.1004279.g004
described in a published report [49]. qPCR of mitochondrial and nuclear DNA was performed as described above.

**Western blot analysis**

Proteins were separated by SDS-PAGE on 10% Tris-acrylamide gels and electrophoretically transferred onto PVDF membranes. Immunodetections with commercial antibodies were performed at the following concentrations: 1:1000 mouse anti-Myc 9E10 (#M4439, Sigma), 1:500 rabbit anti-LONP1 (#NBP1-81734, Novus Biologicals), 1:500 rabbit anti-TFAM (#ab47548, Abcam), 1:1000 rabbit anti-Hsp60 (#4870S, Cell Signaling Technology), 1:1000 mouse anti-VDAC (#MSA03, MitoSciences), 1:2000 mouse anti-OxPhos Complex V subunit β (#A21351, Molecular Probes/Life Technologies), 1:1000 mouse anti-NDUF53 (#ab14711, Abcam), 1:3000 mouse anti-PDH (#MSP07, MitoSciences), 1:50,000 mouse anti-Actin (#MAB1501, Chemicon/Bioscience Research Reagents). The rabbit anti-Mfn had been described previously [50]. The secondary antibody anti-mouse HRP (Sigma) was used at 1:2500 for anti-Myc; 1:10,000 for anti-VDAC and anti-NDUF53; and 1:7500 for anti–Complex V β, anti-PDH, and anti-Actin. The secondary antibody anti-rabbit HRP (Sigma) was used at 1:10,000. Signal was detected using Thermo Scientific electrochemiluminescence reagents. Densitometry

Figure 6. Model of PINK1 processing and degradation. (A) As PINK1 begins to import into mitochondria, the positively charged mitochondrial targeting sequence (MTS) of PINK1 reaches the matrix through the TOM-TIM complex, where MPP recognizes and cleaves this sequence. The MPP-PINK1 cleavage product can then be released into the cytosol, or be further processed within the mitochondria in one of two ways: (B) Rho-7/PARL-mediated cleavage of MPP-PINK1 within the PINK1 transmembrane (TM) domain results in the release of Rho-PINK1 into the cytosol, where it is then degraded by the proteasome (C). Alternatively, (D) MPP-PINK1 is imported into the matrix and degraded by Lon, either directly or following AFG3L2-dependent cleavage of MPP-PINK1 to AFG-PINK1.

doi:10.1371/journal.pgen.1004279.g006
measurements of the western blot images were measured blind to genotype and condition using Fiji software [51]. Normalized western blot data were log-transformed when necessary to stabilize variance before means were compared using Student t test. Each experiment was performed at least three times.

Flow cytometry analysis
Measurement of mitochondrial membrane potential in neural cells was conducted as previously described [28], except that the dissections were conducted in DME/Ham’s F-12 High Glucose media without phenol red (Sigma) with 20 mM HEPE (Sigma), 2.5 mM glutamine (Sigma), and 0.5% trypsin (Invitrogen) at 25°C. Briefly, four adult Drosophila brains per genotype were dissected, dissociated at 25°C, and labeled with 10 nM TMRE at room temperature (Enzo Life Sciences). Samples were maintained at room temperature, in supplemented media with 10 nM TMRE, until flow cytometry analysis was performed. The effect of mitochondrial depolarization on TMRE accumulation was assessed by pretreating neural preps with 100 μM carbonyl cyanide m-chlorophenyl hydrazone (CCCP) for 10 minutes prior to the addition of TMRE. Flow cytometry was performed using a BD FACSCanto or a BD LSRII (BD Biosciences), equipped with a 635 nm laser. The mean TMRE fluorescence of each experimental sample was normalized to the mean fluorescence of the control sample prepared and analyzed on the same day.

Mitochondrial fractionation
Heads from 30 male and 30 female flies were manually homogenized with a pestle in isolation buffer (220 mM mannitol, 68 mM sucrose, 20 mM HEPE pH 7.4, 80 mM KCl, 0.5 mM EGTA, 2 mM Mg(CH3COO)2) containing a protease inhibitor cocktail (#P8340, Sigma). The homogenate was centrifuged at 1500 g for 5 minutes at 4°C to prepare a postnuclear supernatant. The postnuclear supernatant was then subjected to a further round of centrifugation at 10,000 g for 25 minutes at 4°C to pellet mitochondria. The mitochondrial pellet was then either suspended in isolation buffer without protease inhibitors and used in protease protection experiments (see below), or solubilized in SDS-PAGE sample buffer and used in western blot analysis along with the supernatant fractions.

Protease protection assay
Mitochondrial fractions in isolation buffer without protease inhibitors (prepared as described above) were divided in half. One half received a specific concentration of Proteinase K (ProK) (#19131, Qiagen) and the other half received an equal volume of buffer lacking ProK. These samples were incubated on ice for 20 minutes, followed by the addition of phenylmethylsulfonyl fluoride (PMSF) to inhibit ProK. SDS-PAGE sample buffer was then added to the samples, which were then boiled and used in western blot analysis. For experiments involving Triton X-100, equal amounts of ProK were added to both halves of the mitochondrial fraction. Following ProK addition, 1% Triton X-100 was added to one of the two samples, and both samples were incubated for 40 minutes on ice, followed by the addition of PMSF to inhibit ProK. SDS-PAGE sample buffer was then added to the samples, and the samples were boiled and used in western blot analysis.

Immunohistochemistry
Adult thoracic muscle was dissected and then fixed in 4% paraformaldehyde in PBS. The tissue was blocked for one hour in PBS with 0.1% Triton X-100 and 10% fetal bovine serum, then incubated overnight in 1:500 rabbit anti-GFP (#A11122, Life Technologies) and either 1:500 mouse anti-Myc 9E10, 1:500 mouse anti-FLAG (#F3165, Sigma), or 1:2000 mouse anti-Cytochrome C (Cyto C) (#556433, BD Biosciences). The tissue was then washed in PBS with 0.1% Triton X-100 and incubated overnight with 1:500 anti-rabbit Alexa 488 secondary antiserum (#A11034, Life Technologies) and 1:500 (1:1000 for Cyto C) antimouse Alexa 568 secondary antiserum (#A11051, Life Technologies). After final washes, the tissue was mounted in Prolong Gold (#P96794, Invitrogen) and imaged sequentially with 488 nm and 561 nm lasers on an Olympus Fluoview FV1200 (Olympus America) with a 60x objective and 1.5x digital zoom, taken at 1024x1024 pixels and 30 steps of 0.13 μm.

Image analysis
Each stack of 30 images was deconvoluted using Huygens Professional 44.0-p software (Scientific Volume Imaging), using a signal to noise ratio of 20 for the green channel and 18 for the red channel. Co-localization was calculated using the advanced Object Analyzer of the Huygens software, using a threshold of 270 or 2 times the standard deviation of the image, whichever was higher. The seed threshold for objects was set at 2% and the garbage threshold for objects at 500 voxels. At least 6 image stacks were analyzed per condition.

Eye severity score
Flies were assigned to one of three phenotypic categories by an investigator blinded to genotype. Each fly was scored according to the severity of the more greatly affected eye. The three categories were as follows: mild, which ranged from completely WT appearance to bristle misorientation and slight deviation in ommatidial row arrangements; moderate, which consisted of overall ommatidial disorganization and mildly to moderately decreased eye size; and severe, which ranged from greatly reduced eye size to completely absent eyes. The mild, moderate and severe categories were assigned scores of one, two, and three, respectively, and the mean score for each genotype was calculated. Means were compared using Student t test.

Thoracic indentation frequency
Flies were individually examined under a dissecting microscope for the presence of thoracic indentations as previously described [32]. Flies with indentations were assigned a score of one. Flies with no indentations were assigned a score of zero. The mean scores of the experimental and control (sibling) genotypes were compared by Student t test.

Supporting Information
Figure S1 PINK1 mRNA levels in flies bearing one copy of the PINK1-myc transgene. qPCR of reverse transcribed RNA from control animals and those carrying one copy of the genomic PINK1-myc transgene was performed using two different sets of PINK1 primers and compared to the internal housekeeping control transcript of Rsp2L. PCR was performed at least three times. Error bars represent s.e.m. (TIF)

Figure S2 Four PINK1 isoforms are detected in control flies, the smallest of which is less abundant in AFG3L2-deficient flies. (A) A long exposure of a western blot performed on head protein samples from flies bearing a Myc-tagged PINK1 genomic construct and either a control RNAi targeting mCherry (Control-R) or AFG3L2-RNAi (AFG3L2-R1) driven by elav-GAL4. Actin

Lon Regulates PINK1 Degradation and Activity
Lon Regulates PINK1 Degradation and Activity

was used as a loading control. Four bands were detected in the control sample using an anti-Myc antibody and were named according to the protease that appears responsible for their production: FL-PINK1 for unprocessed PINK1; MPP-PINK1 for PINK1 processed by MPP; Rh-PINK1 for PINK1 processed by Rhoo/7-PARL and AFG-PINK1 for PINK1 processed by AFG3L2. (B) Densitometry of the AFG-PINK1 band was performed using Fiji software and the band intensity was normalized to the Actin loading control. This ratio was then normalized to the Control-R AFG-PINK1/Actin ratio. AFG-PINK1 abundance is significantly reduced in AFG3L2-R1 flies. Experiments were repeated at least three times. Error bars represent s.e.m. *p<0.05 by Student t test.

Figure S5

Eye phenotypes of flies expressing RNAi constructs targeting Lon in a WT background. Neither (A) the control RNAi (Control-R) nor the Lon RNAi constructs, (B) Lon-R1 or (C) Lon-R2, resulted in a rough eye phenotype when expressed using the ey-GAL4 driver in an otherwise wild-type background. (TIF)

Figure S6

Mutation in Lon does not suppress a PINK1 null phenotype. No significant suppression of the thoracic indentation frequency of PINK1<sup>B9</sup> null mutants was observed in Lon heterozygotes: PINK1<sup>B9</sup> (n = 23), PINK1<sup>B9</sup>; LON<sup>EP1</sup>/+ (n = 25). Error bars represent s.e.m. (TIF)

Table S1

List of protease genes and RNAi constructs used in screen. (DOCX)

Acknowledgments

We thank Ming Guo, Alex Whitworth, Konrad Zinsmaier, and J.K. Chung for fly stocks and/or antisera. We thank Evelyn Vincow, Leslie Itsara, Kien Trinh, and Glen McDonald for critical input into our work, and Evelyn Vincow and Alex Whitworth for constructive comments on our manuscript.

Author Contributions

Conceived and designed the experiments: RET LJP. Performed the experiments: RET LAA JLB WYL. Analyzed the data: RET JLB. Wrote the manuscript: RET LJP.

References

1. Lee HC, Wei YH (2012) Mitochondria and aging. Advances in Experimental Medicine and Biology 942: 311–327.
2. Karbowski M, Neutner A (2012) Neurodegeneration as a consequence of failed mitochondrial maintenance. Acta Neuropathologica 123: 157–171.
3. Horan MP, Pickaud N, Ballard JW (2012) Review: Quantifying Mitochondrial Dysfunction in Complex Diseases of Aging. The journals of gerontology Series A, Biological sciences and medical sciences 67: 1022–1035.
4. Mari M, Morales A, Colell A, Garcia-Ruiz C, Kapowitz N, et al. (2012) Mitochondrial glutathione: Features, regulation and role in disease. Biochimica et Biophysica Acta 1830(5):3317–28
5. Koppen M, Langer T (2007) Protein degradation within mitochondria: versatile factors Pink1 and Parkin. Disease models & mechanisms 1: 168–174; discussion 769.
6. Taylor ER, Rutter J (2011) Mitochondrial quality control by the ubiquitin-proteasome system. Biochemical Society Transactions 39: 1509–1513.
7. Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, et al. (1998) Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392: 605–608.
8. Valente EM, Abou-Sleiman PM, Caputo V, Muqit MM, Harvey K, et al. (2004) Hereditary early-onset Parkinson’s disease caused by mutations in PINK1. Science 304: 1159–1160.
9. Narendran D, Tanaka A, Suen DF, Youle RJ (2008) Parkin is recruited selectively to impaired mitochondria and promotes their autophagy. The Journal of Cell Biology 179: 602–616.
10. Clarke IE, Dodson MW, Jiang C, Cao JH, Hu JR, et al. (2006) Drosophila pink1 mutants, the Cdc37/Hsp90 chaperones and Parkin all influence the maturation or subcellular distribution of Parkin. Human Molecular Genetics 17: 602–616.
11. Dea E, Plun-Favreau H, Gandhi S, Desmond H, Kijar S, et al. (2011) PINK1 cleavage at position A103 by the mitochondrial protease PARL. Human molecular genetics 20: 867–879.
12. Lin W, Kang UJ (2008) Characterization of PINK1 processing, stability, and subcellular localization. Journal of Neurochemistry 106(1):64–74.
13. Takatori S, Ito G, Iwatsubo T (2008) Cytoplasmic localization and posttranslational degradation of N-terminally cleaved form of PINK1. Neurousci Lett 430: 13–17.
14. Jin SM, Lazarou M, Wang C, Kane LA, Narendran DP, et al. (2010) Mitochondrial membrane potential regulates PINK1 import and proteolytic destabilization by PARL. J Cell Biol 191: 933–942.
15. Schneider H, Arretz M, Wachtler E, Neupert W (1998) Matrix processing peptide of mitochondria: Structure-function relationships. The Journal of Biological Chemistry 265: 9981–9987.
16. Dea E, Plun-Favreau H, Gandhi S, Desmond H, Kijar S, et al. (2011) PINK1 cleavage at position A103 by the mitochondrial protease PARL. Human molecular genetics 17(6): 867–879.
17. Lin W, Kang UJ (2008) Characterization of PINK1 processing, stability, and subcellular localization. Journal of Neurochemistry 106(1):64–74.
18. Takatori S, Ito G, Iwatsubo T (2008) Cytoplasmic localization and posttranslational degradation of N-terminally cleaved form of PINK1. Neurousci Lett 430: 13–17.
19. Welshofen A, Ostaszewski B, Minami Y, Selkoe DJ (2008) Pink1 Parkinson mutations, the Cdc37/Hsp90 chaperones and Parkin all influence the maturation or subcellular distribution of Parkin. Human Molecular Genetics 17: 602–616.
20. Clark IE, Dodson MW, Jiang C, Cao JH, Hu JR, et al. (2006) Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin. Nature 441: 1162–1166.
21. Major T, von Janowsky B, Ruppert T, Mogk A, Voos W (2006) Proteasome analysis of mitochondrial protein turnover: identification of novel substrate proteins of the matrix protease pim1. Mol Cell Biol 26: 762–776.
22. Suzuki CK, Suda K, Wang N, Schatz G (1994) Requirement for the yeast gene (TIF)

 Lon Genetics | www.plosgenetics.org 12 May 2014 | Volume 10 | Issue 5 | e1004279

 treated with Triton X-100 relative to samples without Triton X-100 are shown for the indicated proteins. Experiments were repeated at least three times. Error bars represent s.e.m. (TIF)

Figure S5

Eye phenotypes of flies expressing RNAi constructs targeting Lon in a WT background. Neither (A) the control RNAi (Control-R) nor the Lon RNAi constructs, (B) Lon-R1 or (C) Lon-R2, resulted in a rough eye phenotype when expressed using the ey-GAL4 driver in an otherwise wild-type background. (TIF)

Figure S6

Mutation in Lon does not suppress a PINK1 null phenotype. No significant suppression of the thoracic indentation frequency of PINK1<sup>B9</sup> null mutants was observed in Lon heterozygotes: PINK1<sup>B9</sup> (n = 23), PINK1<sup>B9</sup>; LON<sup>EP1</sup>/+ (n = 25). Error bars represent s.e.m. (TIF)

Table S1

List of protease genes and RNAi constructs used in screen. (DOCX)

Acknowledgments

We thank Ming Guo, Alex Whitworth, Konrad Zinsmaier, and J.K. Chung for fly stocks and/or antisera. We thank Evelyn Vincow, Leslie Itsara, Kien Trinh, and Glen McDonald for critical input into our work, and Evelyn Vincow and Alex Whitworth for constructive comments on our manuscript.

Author Contributions

Conceived and designed the experiments: RET LJP. Performed the experiments: RET LAA JLB WYL. Analyzed the data: RET JLB. Wrote the paper: RET LJP.
Lon Regulates PINK1 Degradation and Activity

26. Nargund AM, Pellegrino MW, Fierez CJ, Baker IM, Haynes CM (2012) Mitochondrial import efficiency of ATFS-1 regulates mitochondrial UPR activation. Science 337: 587–590.

27. Jin SM, Youle RJ (2013) The accumulation of misfolded proteins in the mitochondrial matrix is sensed by PINK1 to induce PARK2/Parkin-mediated mitophagy of polarized mitochondria. Autophagy 9: 1750–1757.

28. Burman JL, Yu S, Poole AC, Decal RB, Pallanck L (2012) Analysis of neural subtypes reveals selective mitochondrial dysfunction in dopaminergic neurons from parkin mutants. Proceedings of the National Academy of Sciences of the United States of America 109: 10438–10443.

29. Frederick RL, McCarthey JM, Cunningham KW, Okamoto K, Shaw JM (2004) Yeast Miro GTPase, Gem1p, regulates mitochondrial morphology via a novel pathway. J Cell Biol 167: 87–98.

30. Lenaers G, Reynier P, Elachouri G, Soukkarieh C, Olichon A, et al. (2009) OPA1 functions in mitochondria and dysfunctions in optic nerve. Int J Biochem Cell Biol 41: 1866–1874.

31. Heath-Engel HM, Shore GC (2006) Mitochondrial membrane dynamics, cristae remodelling and apoptosis. Biochim Biophys Acta 1763: 549–560.

32. Poole AC, Thomas RE, Andrews LA, McBride HM, Whitworth AJ, et al. (2008) The PINK1/Parkin pathway regulates mitochondrial morphology. Proc Natl Acad Sci U S A 105: 1638–1643.

33. Greene JC, Whitworth AJ, Koo I, Andrews LA, Freany MB, et al. (2003) Mitochondrial pathology and apoptotic muscle degeneration in Drosophila parkin mutants. Proc Natl Acad Sci U S A 100: 4078–4083.

34. Park J, Lee SB, Lee S, Kim Y, Song S, et al. (2006) Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin. Nature 441: 1157–1161.

35. Venkataram S, Lee J, Singh K, Lee I, Suzuki CK (2012) Multitasking in the mitochondrion by the ATP-dependent Lon protease. Biochim Biophys Acta 1823: 56–66.

36. Shi G, Lee JR, Grimes DA, Racacho L, Ye D, et al. (2011) Functional alteration of PARL contributes to mitochondrial dysregulation in Parkinson’s disease. Human molecular genetics 20: 1966–1974.

37. Granot Z, Kohler O, Melamed-Book N, Eimerl S, Bahat A, et al. (2007) Turnover of mitochondrial neurodegenerative acute regulatory (SAR) protein by Lon protease: the unexpected effect of proteasome inhibitors. Mol Endocrinol 21: 2164–2177.

38. Gandhi S, Muqit MM, Stanyer L, Healy DG, Abou-Sleiman PM, et al. (2006) PINK1 protein in normal human brain and Parkinson’s disease. Brain : a journal of neurology 129: 1720–1731.

39. Pridgeon JW, Olamann JA, Chinn LS, Li L (2007) PINK1 Protects against Oxidative Stress by Phosphorylating Mitochondrial Chaperone TRAP1. PLoS Biology 5: e172.

40. Becker D, Richter J, Tocilescu MA, Przerborski S, Voos W (2012) Pink1 kinase and its membrane potential (Deltapsi)-dependent cleavage product both localize to outer mitochondrial membrane by unique targeting mode. The Journal of Biological Chemistry 287: 22969–22987.

41. Moreira VA, Haddad D, Crasaeuets K, De Bock PJ, Swerts J, et al. (2014) PINK1 Loss of Function Mutations Affect Mitochondrial Complex I Activity via NduF10 Ubiquinone Uncoupling. Science 344: 203–207.

42. Vincow ES, Merrilwew G, Thomas RE, Shalman NJ, Beyer RP, et al. (2013) The PINK1-Parkin pathway promotes both mitophagy and selective respiratory chain turnover in vivo. Proceedings of the National Academy of Sciences of the United States of America 110: 6400–6405.

43. McLeish GL, Soubanier V, Chen CX, McBride HM, Foa EA (2014) Parkin and PINK1 function in a vesicular trafficking pathway regulating mitochondrial quality control. EMBO J 33: 292–295.

44. Russo GJ, Louie K, Wellington A, Macleod GT, Hu F, et al. (2009) Drosophila Miro is required for both anterograde and retrograde axonal mitochondrial transport. The Journal of neuroscience : the official journal of the Society for Neuroscience 29: 5443–5455.

45. Schuster CM, Davis GW, Fetter RD, Goodman CS (1996) Genetic dissection of structural and functional components of synaptic plasticity. I. Fasciclin II controls synaptic stabilization and growth. Neuron 17: 641–654.

46. Ranganayakulu G, Schulz RA, Olson EN (1996) Wingless signaling induces nautilus expression in the ventral mesoderm of the Drosophila embryo. Developmental Biology 176: 143–148.

47. Hu Y, Sopko R, Foss M, Kelley C, Flockhart I, et al. (2013) FlyPrimerBank: an online database for Drosophila melanogaster gene expression analysis and knockdown evaluation of RNAi reagents. G3 (Bethesda) 3: 1607–1616.

48. Liang D, Salvaterra PM (2011) Robust RT-qPCR data normalization: validation and selection of internal reference genes during post-experimental data analysis. PLoS One 6: e17762.

49. Itsara LS, Kennedy SR, Fox EJ, Yu S, Hewitt JJ, et al. (2014) Oxidative stress is not a major contributor to somatic mitochondrial DNA mutations. PLoS genetics 10: e1003974.

50. Ziviani E, Tao RN, Whitworth AJ (2010) Drosophila parkin requires PINK1 for mitochondrial translocation and ubiquinates mitofusin. Proc Natl Acad Sci U S A 107: 5018–5023.

51. Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, et al. (2012) Fiji: an open-source platform for biological-image analysis. Nat Methods 9: 676–682.